Skip to main content
. Author manuscript; available in PMC: 2011 Jul 28.
Published in final edited form as: Clin Pharmacokinet. 2008;47(6):399–415. doi: 10.2165/00003088-200847060-00004

Fig. 4.

Fig. 4

Time course of recombinant human erythropoietin (rHuEPO) serum concentrations (a) and percentage of reticulocytes counts (b) following subcutaneous administration of rHuEPO at different doses. The lines and the shaded area represent the median and 90% prediction interval from the posterior predictive check, respectively.